BioLife Solns Q1 2024 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $16.20M Miss $26.01M Estimate
BioLife Solns Q1 2024 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $16.20M Miss $26.01M Estimate
BioLife Solns 2024年第一季度GAAP每股收益（0.22）超過預期（0.28）美元，銷售額爲1,620萬美元，低於2,601萬美元的預期
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28) by 21.43 percent. The company reported quarterly sales of $16.20 million which missed the analyst consensus estimate of $26.01 million by 37.71 percent. This is a 57.03 percent decrease over sales of $37.70 million the same period last year.
BioLife Solns（納斯達克股票代碼：BLFS）公佈的季度虧損爲每股0.22美元，比分析師普遍預期的0.28美元（0.28美元）高出21.43％。該公司公佈的季度銷售額爲1,620萬美元，比分析師普遍預期的26001萬美元低37.71％。這比去年同期的3,770萬美元銷售額下降了57.03％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。